Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close change Change (%) Open High Low

VirBiotechnology news

Latest news

Show more
Noah Lee 2025 Sep 15, 15:20

Gold Rush in the Trump Era: Investors Seek Haven Amid Uncertainty

Noah Lee 2025 Sep 15, 13:20

Musk's Tesla Stock Purchase Fuels Confidence, Sends Shares Soaring

Liam James 2025 Sep 15, 13:20

Trump Proposes Semiannual Reporting for US Companies: Cost Savings or Reduced Transparency?

Ava Grace 2025 Sep 15, 12:20

Russia Tests Zircon Missile, Drills with Belarus; US Observes Amid Geopolitical Maneuvering

Ava Grace 2025 Sep 15, 11:20

Fed Rate Hike Outlook 2025: Inflation and Jobs Market in Focus

Emma Rose 2025 Sep 15, 10:20

India Gold Demand Forecast to Weaken During Festival Season Due to High Prices

Noah Lee 2025 Sep 15, 09:20

Fed Rate Cut Outlook Amid Sticky Inflation and Labor Market Signals

Emma Rose 2025 Sep 15, 09:20

US Job Market Slowdown: Trade Turmoil's Impact and Future Outlook

Info

Spread

0.03

Spread (%)

0.6237 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Market open

Monday

13:31 - 19:59

Tuesday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

694579968

Shares Outstanding

138916000

Earnings Date (Next)

0000-00-00

instr__dividend_date

instr__ex_dividend_date

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

EPS

-4.01

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Trustpilot